Prostate Cancer - Results from #26160

Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer - Abstract March 20, 2012

Communicating health decisions: An analysis of messages posted to online prostate cancer forums - Abstract March 19, 2012

Natural orifice translumenal endoscopic radical prostatectomy - Abstract March 19, 2012

Prostate-cancer mortality at 11 years of follow-up - Abstract March 16, 2012

The value of triple antibody (34βE12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins - Abstract March 16, 2012

Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: A radical prostatectomy correlated series - Abstract March 16, 2012

Study on the distribution features of bone metastases in prostate cancer - Abstract March 16, 2012

Narrow safety range of intraoperative rectal irradiation exposure volume for avoiding bleeding after seed implant brachytherapy - Abstract March 16, 2012

Emerging novel therapies for advanced prostate cancer - Abstract March 16, 2012

Tissue biomarkers for prostate cancer radiation therapy - Abstract March 15, 2012

Complications and functional results of surgery for locally advanced prostate cancer - Abstract March 15, 2012

Risk factors for the onset of prostatic cancer: Age, location, and behavioral correlates - Abstract March 15, 2012

Abiraterone acetate: Oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer - Abstract March 15, 2012

Improvement in prostate cancer survival over time: A 20-year analysis - Abstract March 15, 2012

Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy - Abstract March 14, 2012

Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy - Abstract March 14, 2012

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer - Abstract March 14, 2012

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer - Abstract March 14, 2012

Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): An observational study in a single institution - Abstract March 14, 2012

CD10 is inversely associated with nuclear factor-Kappa B and predicts biochemical recurrence after radical prostatectomy - Abstract March 13, 2012

Page 1309 of 1434